Trichinosis future or investigational therapies

Trichinosis Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Trichinosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Trichinosis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Trichinosis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Trichinosis future or investigational therapies
CDC on Trichinosis future or investigational therapies
Trichinosis future or investigational therapies in the news
Blogs on Trichinosis future or investigational therapies
Directions to Hospitals Treating Trichinosis
Risk calculators and risk factors for Trichinosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Danitza Lukac

Vaccine research

• There are currently no vaccines for trichinosis, although experimental mice studies have suggested a possibility
• In one study, microwaved Trichinella larvae were used to immunize mice, which were subsequently infected. Depending on dosage and the frequency of immunization, results ranged from a decreased larval count to complete protection from trichinosis
• Another study, used extracts and excretory-secretory products from first stage larvae to produce an oral vaccine. To prevent the gastric acids from dissolving the antigens before reaching the small intestine, scientists encapsulated the antigens in a microcapsule made of copolymers. This vaccine significantly increased CD4+ cells and increased antigen-specific serum IgG and IgA, resulting in a statistically significant reduction in the average number of adult worms in the small intestine of mice. The significance of this approach is that if the white blood cells in the small intestine have been exposed to Trichinella antigens (through vaccination) then, when an individual gets infected, the immune system will respond to expel the worms from the small intestine fast enough to prevent the female worms from releasing their larvae
• Another study tested a DNA vaccine on mice which "induced a muscle larvae burden reduction in BALB/c mice by 29% in response to T. spiralis infection"
• Researchers trying to develop a vaccine for Trichinella have tried to using either "larval extracts, excretory-secretory antigen, DNA vaccine, or recombinant antigen protein"